Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

Int J Gynecol CancerJun 19, 2026 (epub)
Clinical ResearchOncology (Medical)

Vanda Salutari, Claudia Marchetti, Elena Giudice et al.

✦ AI-curated · Sources linked

In 30 seconds

The NUVOLA trial, a phase II open-label study, evaluated the addition of olaparib to neoadjuvant chemotherapy in 36 patients with BRCA-mutated advanced epithelial ovarian cancer. The study found a complete pathological response in 8.6% of patients, suggesting that concurrent use of olaparib does not enhance the efficacy of platinum-based chemotherapy in this setting.

Key findings

  • Complete pathological response was achieved in 8.6% of patients.
  • The overall response rate was 89% at the end of neoadjuvant treatment.
  • Median progression-free survival was 39.7 months.
  • 86% of patients experienced treatment-related adverse events.

Why it matters

Understanding the efficacy of concurrent olaparib with chemotherapy is crucial for optimizing treatment strategies in BRCA-mutated ovarian cancer, as it may influence future therapeutic approaches and patient management.

Source

PubMed · PMID 42435644

Published in Int J Gynecol Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.